The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Insulet missed slightly on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly. GAAP loss per share dropped.
Margins grew across the board.
Insulet recorded revenue of $57.8 million. The 16 analysts polled by S&P Capital IQ predicted net sales of $58.9 million on the same basis. GAAP reported sales were 23% higher than the prior-year quarter's $47.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.21. The 14 earnings estimates compiled by S&P Capital IQ anticipated -$0.22 per share. GAAP EPS were -$0.21 for Q4 against -$0.30 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.8%, 130 basis points better than the prior-year quarter. Operating margin was -10.5%, 820 basis points better than the prior-year quarter. Net margin was -17.6%, much better than the prior-year quarter.
Next quarter's average estimate for revenue is $60.2 million. On the bottom line, the average EPS estimate is -$0.20.
Next year's average estimate for revenue is $261.8 million. The average EPS estimate is -$0.49.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 69 members out of 109 rating the stock outperform, and 40 members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give Insulet a green thumbs-up, and 13 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Insulet is outperform, with an average price target of $24.24.
Is Insulet the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Insulet to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.